Literature DB >> 20451557

Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.

Michael R Jordan1, Mary Kearney, Sarah Palmer, Wei Shao, Frank Maldarelli, Eoin P Coakley, Colombe Chappey, Christine Wanke, John M Coffin.   

Abstract

To compare standard PCR/cloning and single genome sequencing (SGS) in their ability to reflect actual intra-patient polymorphism of HIV-1 populations, a total of 530 HIV-1 pro-pol sequences obtained by both sequencing techniques from a set of 17 ART naïve patient specimens was analyzed. For each specimen, 12 and 15 sequences, on average, were characterized by the two techniques. Using phylogenetic analysis, tests for panmixia and entropy, and Bland-Altman plots, no difference in population structure or genetic diversity was shown in 14 of the 17 subjects. Evidence of sampling bias by the presence of subsets of identical sequences was found by either method. Overall, the study shows that neither method was more biased than the other, and providing that an adequate number of PCR templates is analyzed, and that the bulk sequencing captures the diversity of the viral population, either method is likely to provide a similar measure of population diversity. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20451557      PMCID: PMC3949620          DOI: 10.1016/j.jviromet.2010.04.030

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  18 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice.

Authors:  Katy Dewitte; Colette Fierens; Dietmar Stöckl; Linda M Thienpont
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

3.  Multiple sequence alignment with the Clustal series of programs.

Authors:  Ramu Chenna; Hideaki Sugawara; Tadashi Koike; Rodrigo Lopez; Toby J Gibson; Desmond G Higgins; Julie D Thompson
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

4.  Antiretroviral drug resistance mutations in antiretroviral-naive prisoners.

Authors:  David R Stone; Colleen Corcoran; Alysse Wurcel; Barbara McGovern; James Quirk; Arthur Brewer; Lorraine Sutton; Richard T D'Aquila
Journal:  Clin Infect Dis       Date:  2002-09-11       Impact factor: 9.079

5.  A robust measure of HIV-1 population turnover within chronically infected individuals.

Authors:  G Achaz; S Palmer; M Kearney; F Maldarelli; J W Mellors; J M Coffin; J Wakeley
Journal:  Mol Biol Evol       Date:  2004-06-23       Impact factor: 16.240

6.  Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates.

Authors:  L Q Zhang; P Simmonds; C A Ludlam; A J Brown
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

7.  HIV quasispecies and resampling.

Authors:  S L Liu; A G Rodrigo; R Shankarappa; G H Learn; L Hsu; O Davidov; L P Zhao; J I Mullins
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

8.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

9.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.

Authors:  Jesus F Salazar-Gonzalez; Elizabeth Bailes; Kimmy T Pham; Maria G Salazar; M Brad Guffey; Brandon F Keele; Cynthia A Derdeyn; Paul Farmer; Eric Hunter; Susan Allen; Olivier Manigart; Joseph Mulenga; Jeffrey A Anderson; Ronald Swanstrom; Barton F Haynes; Gayathri S Athreya; Bette T M Korber; Paul M Sharp; George M Shaw; Beatrice H Hahn
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

View more
  47 in total

1.  Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C.

Authors:  Sivapragashini Danaviah; Tulio de Oliveira; Michelle Gordon; Shunmugam Govender; Paul Chelule; Sureshnee Pillay; Thajasvarie Naicker; Sharon Cassol; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-17       Impact factor: 2.205

2.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Authors:  Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley
Journal:  World J AIDS       Date:  2013-06

3.  Development of a Versatile, Near Full Genome Amplification and Sequencing Approach for a Broad Variety of HIV-1 Group M Variants.

Authors:  Andrew N Banin; Michael Tuen; Jude S Bimela; Marcel Tongo; Paul Zappile; Alireza Khodadadi-Jamayran; Aubin J Nanfack; Josephine Meli; Xiaohong Wang; Dora Mbanya; Jeanne Ngogang; Adriana Heguy; Phillipe N Nyambi; Charles Fokunang; Ralf Duerr
Journal:  Viruses       Date:  2019-04-01       Impact factor: 5.048

4.  Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Authors:  Katlego Sojane; Richard T Kangethe; Christina C Chang; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

5.  Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years.

Authors:  Ishla Seager; Simon A Travers; Michael D Leeson; Amelia C Crampin; Neil French; Judith R Glynn; Grace P McCormack
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-29       Impact factor: 2.205

6.  Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N.

Authors:  Madina Shakirzyanova; Lily Tsai; Wuze Ren; Agegneu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

7.  The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Authors:  Paula Lerner; Moraima Guadalupe; Richard Donovan; Jason Hung; Jason Flamm; Thomas Prindiville; Sumathi Sankaran-Walters; Michael Syvanen; Joseph K Wong; Michael D George; Satya Dandekar
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

8.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

9.  Interleukin-7 promotes HIV persistence during antiretroviral therapy.

Authors:  Claire Vandergeeten; Rémi Fromentin; Sandrina DaFonseca; Mariam B Lawani; Irini Sereti; Michael M Lederman; Moti Ramgopal; Jean-Pierre Routy; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

10.  HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Authors:  Frank Maldarelli; Mary Kearney; Sarah Palmer; Robert Stephens; JoAnn Mican; Michael A Polis; Richard T Davey; Joseph Kovacs; Wei Shao; Diane Rock-Kress; Julia A Metcalf; Catherine Rehm; Sarah E Greer; Daniel L Lucey; Kristen Danley; Harvey Alter; John W Mellors; John M Coffin
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.